ProCE Banner Activity

CLL Studies Presented at the 2016 Hematology Meeting Confirm Ibrutinib’s Long-term Efficacy and Suggest Benefit From Second-line Agents

Clinical Thought
Do you know how recent CLL results presented at ASH 2016 could change your practice? Read my thoughts on ibrutinib and what to do after treatment failure.

Released: January 06, 2017

Expiration: January 05, 2018

No longer available for credit.

Share

Faculty

Jeffrey A. Jones

Jeffrey A. Jones, MD, MPH

Associate Professor of Medicine
Section Head of CLL/HCL
Division of Hematology
The Ohio State University
Columbus, Ohio

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Genentech Roche Virology

Janssen Pharmacyclics

Pharmacyclics Inc

Faculty Disclosure

Primary Author

Jeffrey A. Jones, MD, MPH

Associate Professor of Medicine
Section Head of CLL/HCL
Division of Hematology
The Ohio State University
Columbus, Ohio

Jeffrey A. Jones, MD, MPH, has disclosed that he has received consulting fees and funds for contracted research from AbbVie, Genentech, Gilead Sciences, Janssen, and Pharmacyclics.